• Twitter
  • Linkedin
CHOP: Coalition of Hematology and Oncology Practices
  • HOME
  • ABOUT
    • MISSION & GOALS
    • HISTORY
    • BOARD OF DIRECTORS
  • MEMBER
    • CORPORATE MEMBERS
    • BECOME A CORPORATE MEMBER
    • BECOME A PRACTICE MEMBER
    • MEMBER DIRECTORY
  • BECOME A MEMBER
  • ADVOCACY
    • SENATORS
    • REPRESENTATIVES
    • STATE LEGISLATURE INTERACTIVE MAP
  • INDUSTRY ANNOUNCEMENTS
  • CHOP RESOURCE NETWORK
    • Sponsor Access
    • Membership Access
      • Caregiving
  • MY ACCOUNT
  • CONTACT
Select Page

A GREAT RESOURCE TO SHARE WITH YOUR PATIENTS. SEE HOW BIOSIMILARS ARE MADE, AND WHY THEY CAN MAKE A DIFFERENCE.

Format: Video (4:21) Presented by Pfizer Posted 5/2022

FIND OUT THE ROLE THAT IMMUNOGENICITY–THE POTENTIAL TO ELICIT AN IMMUNE RESPONSE–PLAYS IN THE APPROVAL OF BIOSIMILARS.

Format: Video (4:21) Presented by Pfizer Posted 5/2022

TAKE A CLOSER LOOK AT EXTRAPOLATION TO SEE HOW BIOSIMILARS MAY LEAD TO FASTER APPROVALS AND POTENTIAL BENEFITS.

Format: Video (5:33) Presented by Pfizer Posted 5/2022

DISCOVER HOW COMPARATIVE CLINICAL STUDIES PLAY A SUPPORTING, RATHER THAN CENTRAL, ROLE IN THE APPROVAL OF BIOSIMILARS.

Format: Video (5:03) Presented by Pfizer Posted 5/2022

SEE HOW BIOSIMILARS ARE EVALUATED BASED ON THE TOTALITY OF EVIDENCE, INCLUDING ANALYTICAL, NONCLINICAL, CLINICAL PHARMACOLOGY, PK/PD, AND CLINICAL STUDIES.

Format: Video (4:11) Presented by Pfizer Posted 5/2022
« Older Entries
© 2023 CHOP: COALITION OF HEMATOLOGY AND ONCOLOGY PRACTICES